The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

Minneapolis-based life sciences firm Bio-Techne Corp. on Wednesday said it’s reached a deal to buy Austin, Texas-based Asuragen for up to $320 million. Under the terms of the deal, Bio-Techne will pay ...

Life sciences company Bio-Techne (NASDAQ:TECH) will be announcing earnings results this Wednesday before market hours. Here’s what investors should know. Bio-Techne beat analysts’ revenue expectations ...

MINNEAPOLIS, Sept. 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today released its 2025 Corporate ...

MINNEAPOLIS, July 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership to distribute Spear Bio's next-generation ultrasensitive immunoassays, enabling ...

Why Bio-Techne Is Back on Investors Radar Bio-Techne (TECH) has been drifting after a tough year, but recent gains over the past 3 months suggest investors are rethinking the story as growth and ...

--Bio-Techne Corporation today reported its financial results for the third quarter ending March 31, 2025. Delivered adjusted EPS of $0.56 compared to $0.48 one year ago. Improved pharma end market ...

Bio-Techne Corp. topped $1 billion in full-year sales for the first time, its latest results showed Thursday, and the Minneapolis-based life science firm said it is beginning a two-year leadership ...

Bio-Techne (NASDAQ:TECH) will release its quarterly earnings report on Wednesday, 2024-10-30. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Bio-Techne to report ...

Bio-Techne (TECH) prevailed on another claim that Miltenyi Biotec KG commercialized antibodies developed based on information obtained by reverse engineering Bio-Techne’s proprietary R&D Systems ...

A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir ...

Bio-Techne Corp. will spend $257 million for a 20% stake of New Brighton company that makes cell culture devices. If financial targets are met, Bio-Techne could buy the rest of Wilson Wolf ...